Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
Aprea Therapeutics (NASDAQ:APRE), a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The presentation is scheduled for Tuesday, September 9, 2025, at 3:30 PM ET at the Lotte New York Palace Hotel in New York. A webcast of the presentation will be accessible for 90 days through the company's investor relations website.
Aprea Therapeutics (NASDAQ:APRE), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie oncologiche innovative, ha annunciato la sua partecipazione al 27掳 H.C. Wainwright Annual Global Investment Conference.
La presentazione 猫 programmata per marted矛 9 settembre 2025 alle 15:30 ET presso il Lotte New York Palace Hotel di New York. Una webcast della presentazione sar脿 disponibile per 90 giorni sul sito web per gli investitori della societ脿.
Aprea Therapeutics (NASDAQ:APRE), una compa帽铆a biofarmac茅utica en etapa cl铆nica centrada en el desarrollo de tratamientos oncol贸gicos innovadores, anunci贸 su participaci贸n en la 27.陋 Conferencia Anual Global de Inversi贸n de H.C. Wainwright.
La presentaci贸n est谩 programada para el martes 9 de septiembre de 2025 a las 3:30 p.m. ET en el Lotte New York Palace Hotel de Nueva York. La transmisi贸n web de la presentaci贸n estar谩 disponible durante 90 d铆as en la p谩gina de relaciones con inversores de la compa帽铆a.
Aprea Therapeutics (NASDAQ:APRE)電� 順侅嫚鞝侅澑 鞎� 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎届偓搿�, H.C. Wainwright 鞝�27須� 鞐半 旮�搿滊矊 韴瀽 旖橅嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
氚滍憸电� 2025雲� 9鞗� 9鞚� 頇旍殧鞚� 霃欕秬鞁滉皠(ET) 鞓ろ泟 3鞁� 30攵�鞐� 雺挫殨 Lotte New York Palace Hotel鞐愳劀 歆勴枆霅╇媹雼�. 氚滍憸 鞗轨簮鞀ろ姼電� 須岇偓鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 90鞚缄皠 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
Aprea Therapeutics (NASDAQ:APRE), une soci茅t茅 biopharmaceutique en phase clinique ax茅e sur le d茅veloppement de traitements innovants contre le cancer, a annonc茅 sa participation 脿 la 27e conf茅rence annuelle mondiale sur l'investissement H.C. Wainwright.
La pr茅sentation est pr茅vue le mardi 9 septembre 2025 脿 15h30 ET au Lotte New York Palace Hotel 脿 New York. Un webdiffusion de la pr茅sentation sera accessible pendant 90 jours via le site des relations investisseurs de la soci茅t茅.
Aprea Therapeutics (NASDAQ:APRE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung innovativer Krebsbehandlungen spezialisiert hat, gab seine Teilnahme an der 27. H.C. Wainwright Annual Global Investment Conference bekannt.
Die Pr盲sentation ist geplant f眉r Dienstag, den 9. September 2025, um 15:30 Uhr ET im Lotte New York Palace Hotel in New York. Ein Webcast der Pr盲sentation wird f眉r 90 Tage 眉ber die Investor-Relations-Website des Unternehmens verf眉gbar sein.
- None.
- None.
DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.聽(Nasdaq: APRE) (鈥淎prea鈥�, or the 鈥淐ompany鈥�), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities聽while minimizing damage to healthy cells, today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference, to take place September 8-10, 2025, in New York.
Presentation Details
Date/ time: Tuesday, September 9聽at聽3:30 PM聽ET
Location: Lotte New York Palace Hotel
Webcast link:聽
The webcast will be available for 90 days at the link above or on the Aprea Investors page, under 鈥淣ews & Events.鈥�
About Aprea
Aprea鈥檚 mission is to develop novel cancer therapies that target cancer cells directly, while sparing healthy ones. By exploiting unique vulnerabilities in cancer cell mutations, this approach is designed to eradicate tumors while minimizing harm to normal tissues, thereby reducing the risk of toxicity often associated with conventional chemotherapy and other treatments. Aprea鈥檚 lead programs include APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a macrocyclic small molecule ATR inhibitor, both currently in clinical development for solid tumor indications. For more information, please visit the company website at聽.
The Company may use, and intends to use, its investor relations website at聽聽as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Investor Contact:
Mike Moyer
LifeSci Advisors
FAQ
When is Aprea Therapeutics (APRE) presenting at the H.C. Wainwright Conference?
How long will the APRE conference presentation webcast be available?
What is Aprea Therapeutics' (APRE) main business focus?
Where can investors access Aprea Therapeutics' H.C. Wainwright presentation?
